NCT05000762Withdrawn
Zinc Supplementation Improves Cardiovascular Morbidity in Patients With Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 12 Dec 2023
Reason given: Sponsor no longer has support available.
Brief summary (registry, in English)
Oral zinc supplementation in patients with diabetes mellitus can improve glycemic control. However, there is reluctance to recommend zinc supplements to these patients because there is no evidence that the zinc-dependent improvement in glycemic control offers protections from the cardiovascular morbidities associated with diabetes mellitus, especially myocardial infarction and thrombotic stroke. The investigators are conducting a randomized, double blind, cross over study to test the hypothesis that oral zinc supplementation will block the enhanced cardiovascular, cerebrovascular, and platelet reactivity that lead to myocardial infarction and stroke in research participants with diabetes mellitus.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 3 Aug 2021
- Start date
- 1 Jun 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Wayne State University
- Diseases
- Type 2 diabetes
- NCT number
- NCT05000762
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant women
- Anyone unable to understand or give informed consent
Who the study is looking for
- Only patients with stable type 2 diabetes mellitus or pre-diabetes (HgbA1c between 6% - 9%) and who are otherwise healthy
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wayne State University School of Medicine | Detroit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.